FDA 483 - ImClone Systems, LLC - August 25, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of ImClone Systems, LLC, a drug substance manufacturer located at 33 ImClone Drive, Branchburg, NJ 08876, was conducted on 07/26-29/2022, 08/02-05/2022, and 08/22-25/2022. The inspection, issued to Nellie D. Clark, VP, Site Head of Manufacturing, identified two observations.
Observation 1 noted a failure to control the disposition and availability of drug substances within the scope of deviation investigations before satisfactory quality unit evaluation. Specifically, drug substance lots implicated in Deviation Investigation TR# (b)(4) (initiated 06/25/2022 for unknown debris in a production CIP tank) were not adequately controlled. Additionally, not all implicated drug substance lots, such as Material Number: (b)(4) Dulaglutide (b)(4) Drug Substance, Batch: (b)(4), were included in the initial deviation record (b)(4) populated on 06/28-29/2022. The closed deviation record (TR# (b)(4), 07/25/2022) also omitted several implicated drug substances, including Olaratumab (IMC-3G3), Ramucirumab, and Necitumumab.
Observation 2 cited
ID · bb047a85-d942-468f-ba8c-12d4c36b0558